Daré Bioscience posts Phase 1 data showing topical sildenafil cream well tolerated in postmenopausal women
DARE•Study findings and development timeline
The study showed the cream was well tolerated, with limited drug exposure in the bloodstream versus oral sildenafil.
The data supported localized delivery aimed at improving genital arousal while reducing systemic side effects.
Prescription dispensing for the 503B compounded version is expected to start in Q3 2026 as FDA-pathway work continues.
Phase 1 results published for topical sildenafil cream
Daré Bioscience disclosed publication of Phase 1 results for its topical sildenafil cream in healthy postmenopausal women.
The results were already presented via a peer-reviewed journal publication, not flagged for a future medical meeting.
